← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 10.3% to $26.98B, while Net income increased 2.5% to $4.16B.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $26.98BOK
- Profitability — Net income $4.16BOK
- Cash generation — Free cash flow $5.00BOK
- Accounting — Formula-grey distress score · manipulation and earnings-quality screens not computedNote
- Insiders — 0 buys; 5 sells in 365 daysNote
- Capital — dividends paid were $1.70B; share repurchases were $2.01BNote
Business
MARSH & MCLENNAN COMPANIES, INC.: Other regulatory bodies, such as investment, securities, and futures licensing authorities, govern certain of the Company's Risk and Insurance services activities.
Where the revenue comes from
Fiscal 2025, as MARSH & MCLENNAN COMPANIES, INC. reports it. History and quarterly detail are in the app.
- Risk and Insurance Services$17.3B
- Consulting$9.8B
Leadership changes
From MARSH & MCLENNAN COMPANIES, INC.'s own filings, the day they're filed.
- Mark McGivney · President · appointmenteff. 2026-04-08
- Nick Studer · President · appointmenteff. 2026-04-01
- Peter Harrison · appointmenteff. 2026-02-25
Latest filings
- 8-K · Company announcement2026-06-04
- 8-K · Company announcement2026-05-22
- 10-Q · Quarterly report2026-04-16
- 8-K · Company announcement2026-04-16
- 8-K · Company announcement2026-04-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about MARSH & MCLENNAN COMPANIES, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.